Mibefradil (Di HCl)

Mibefradil (Di HCl) is a calcium-channel blocking agent, that primarily acts on fast T-type calcium channels. It was introduced for the management of hypertension and angina pectoris. The drug has been withdrawn from market due to increasing reports of serious interactions with wide range of drugs.

Brands
Adult Dose
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin. It belongs to Calcium Channel Blocker pharmacological group.The Molecular Weight of Mibefradil (Di HCl) is 568.56.
Contraindications
Mibefradil (Di HCl) is contraindicated in conditions like Myocardial infarction,Sick sinus syndrome,Hypersensitivity,Pregnancy,Lactation,Moderate to severe heart failure,Second or third degree A-V block,Hepatic impairment.
Effects
Mibefradil (Di HCl) produces potentially life-threatening effects which include Symptomatic slow junctional rhythm. which are responsible for the discontinuation of Mibefradil (Di HCl) therapy.The signs and symptoms that are produced after the acute overdosage of Mibefradil (Di HCl) include Bradycardia, Hypotension, Peripheral vasodilation, High degree AV block.The symptomatic adverse reactions produced by Mibefradil (Di HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Thrombocytopenia, Angioedema, Leg edema.
Indications
Mibefradil (Di HCl) is primarily indicated in conditions like Angina, Essential hypertension, and can also be given in adjunctive therapy as an alternative drug of choice in Congestive heart failure.
Interactions
Mibefradil (Di HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAstemizoleAtorvastatinCisaprideCyclosporin ADesipramine (HCl)DigoxinImipramine (HCl)LovastatinMethylergonovineBased on in vitro inhibition data, coadministration with mibefradil may increase the plasma concentrations of drugs that are substrates of CYP450 2D6 and/or 3A4. The mechanism is decreased clearance due to inhibition of these isoenzymes by mibefradil.ModerateCaution is advised if mibefradil must be used concomitantly with medications that undergo metabolism by CYP450 2D6 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever mibefradil is added to or withdrawn from therapy. Metoprolol (Tartrate)Phenytoin (Na)QuinidineSimvastatinTerfenadineThioridazine (HCl) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to Pregnant Mothers, and patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tab Store at room temperature.
Warnings
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.